Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
W. Labaki (Ann Arbor, United States of America), T. Gu (Ann Arbor, United States of America), S. Murray (Ann Arbor, United States of America), J. Curtis (Ann Arbor, United States of America), R. Bowler (Denver, United States of America), R. Barr (New York, United States of America), E. Hoffman (Iowa City, United States of America), A. Comellas (Iowa City, United States of America), N. Hansel (Baltimore, United States of America), C. Cooper (Los Angeles, United States of America), R. Kanner (Salt Lake City, United States of America), R. Paine Iii (Salt Lake City, United States of America), G. Criner (Philadelphia, United States of America), M. Dransfield (Birmingham, United States of America), M. Mcdonald (Birmingham, United States of America), J. Krishnan (Chicago, United States of America), E. Bleecker (Tucson, United States of America), S. Peters (Winston-Salem, United States of America), P. Woodruff (San Francisco, United States of America), W. O'Neal (Chapel Hill, United States of America), W. Diao (Beijing, China), B. He (Beijing, China), F. Martinez (New York, United States of America), T. Standiford (Ann Arbor, United States of America), K. Stringer (Ann Arbor, United States of America), M. Han (Ann Arbor, United States of America). Altered serum metabolomics in COPD: analysis of the SPIROMICS cohort. 580

Member's Comments

No comment yet.

Related content which might interest you: Plasma metabolomic signature in COPD patients: Associations to proteomic profile and clinical outcomes Source: Annual Congress 2013 –COPD mechanisms Year: 2013 Metabolomic profiling differences among asthma, COPD and healthy controls: a LC-MS-based metabolomics analysis Source: International Congress 2019 – Evaluation of basic science in airway diseases Year: 2019 Novel method of expressing serum biomarkers profiling in COPD patients: The heatmap-clinical pattern profile Source: Annual Congress 2010 - COPD: treatment and monitoring Year: 2010 Gene signalling heterogeneity in exacerbations of COPD determined by microarray analysis of PBMC mRNA Source: International Congress 2015 – Respiratory translational research: novel mechanisms, diagnostic markers and Space Odyssey Year: 2015 Metabolomic analysis of severe COPD. Study of biomarkers in the CHAIN cohort. Source: International Congress 2019 – New molecular signatures in COPD, lung cancer and a1-antitrypsin deficiency Year: 2019 NMR serum metabolomics for understanding the pathophysiology of COPD associated PH: A pilot study Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Novel patterns of serum biomarkers profiling using minimal important clinical outcomes (MICO) in the longidutinal study BODE cohort of COPD patients Source: Annual Congress 2010 - COPD: symptoms and staging Year: 2010 COPD phenotypes revealed by the integrated sputum microbiome and proteome analysis in COPDMAP cohort Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations Year: 2019 Variations in C-reactive protein gene and COPD: tagging SNPs analysis in case-control study Source: Annual Congress 2007 - Acute and chronic lung injury and its repair: novel molecular insight Year: 2007 Stability of serum biomarkers and their associations with clinical outcomes in COPD patients and controls: a longitudinal study Source: Annual Congress 2009 - Biomarkers and biology in COPD Year: 2009 Identification and analysis of clinical phenotypes in COPD patients: PALOMB Cohort Source: Virtual Congress 2021 – COPD burden, epidemiology and management Year: 2021 Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers Source: International Congress 2014 – Markers Year: 2014 Simultaneous analysis of sputum and serum biomarkers in adult asthma Source: International Congress 2019 – Clinical implications of asthma management Year: 2019 Genomic analysis of CC16 as a biomarker for COPD Source: International Congress 2018 – Role of omics in population studies Year: 2018 Muscle phenotypes in COPD patients: An exploratory cluster analysis Source: Annual Congress 2012 - The best posters on physical inactivity, muscle dysfunction and exercise intolerance Year: 2012 A comparative proteomic profiling of the human erythrocyte membrane in COPD patients Source: Annual Congress 2009 - New results in molecular pathology and functional genomics of non-neoplastic lung diseases Year: 2009 A proteomic approach to the progression of COPD: protein expression profile in induced sputum samples Source: Eur Respir J 2006; 28: Suppl. 50, 824s Year: 2006 Microarray profiling of COPD patients versus non-COPD smokers reveals possible disease biomarkers Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases Year: 2013 Analysis of serum prohepcidin and hepcidin levels in COPD patients by stages and by patient cathegory Source: Annual Congress 2013 –COPD treatment Year: 2013 Longitudinal validation of clinical COPD phenotypes identified by cluster analysis Source: Annual Congress 2011 - COPD diagnosis Year: 2011